Erythropoietin in Acute Myocardial Infarction
Acute Myocardial Infarction
About this trial
This is an interventional treatment trial for Acute Myocardial Infarction focused on measuring acute myocardial infarction, primary angioplasty
Eligibility Criteria
Inclusion Criteria: Male or female >18 years of age Weight between 50 kg and 120 kg Suspected of having his/her first-documented STEMI Symptoms of ischemia of >20 min with < 6h prior to PCI Either 1mm ST elevation in at least two contiguous limb leads or >2mm ST elevation in 2 contiguous chest leads Primary PCI to occur within 8h from the onset of symptoms Women of childbearing potential must have a negative pregnancy test Exclusion Criteria: Contraindications to MRI scanning History or ECG evidence of previous STEMI Cardiogenic shock NYHA class III-IV heart failure LBBB or AF on ECG; 6.Major trauma, major surgery, eye, spinal cord, or brain surgery within the last 3 months Significant hepatic disturbance Chronic renal impairment (Creatinine >200µmol/L) Stroke or TIA <6 months Pregnancy or breast-feeding Dependence on alcohol or other DOA Significant psychiatric/neurologic disease that would prevent adherence to the requirements of the protocol Significant immunocompromise (including, but not limited to AIDS and immune-suppressive therapy Current treatment with human recombinant erythropoietin Current hemodialysis or peritoneal dialysis
Sites / Locations
- Hammersmith Hospital NHS Trust
- King's College London